Key facts
- EnteroBiotix’s last known valuation is $66.8M (Mar 2024).
- It has raised $94.2M across 6 recorded rounds; the latest was Early Stage VC ($5.3M) in Mar 2026.
- Notable investors include Innovate UK, Scottish Enterprise, SyndicateRoom, The Scottish National Investment Bank, Bank Workers Charity — 20 tracked in total.
- EnteroBiotix has filed 5 Form Ds with the SEC since 2022, most recently Jul 2025 ($1.4M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for EnteroBiotix
Funding rounds
6 roundsAbout EnteroBiotix
Developer of microbiome-modulating drugs designed to restore health and prevent bacterial infections. The company focuses on creating microbial therapeutics for patients with serious unmet medical needs and addresses them through a pipeline of tailored, high-diversity products that fortify and restore the microbiome, enabling physicians to prevent and treat debilitating infections and diseases.
- Sector
- Healthcare
- HQ
- Bellshill, United Kingdom
- Founded
- 2017
- Employees
- 49
- Website
- enterobiotix.com/
- Ownership
- Privately Held (backing)
EnteroBiotix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EnteroBiotix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EnteroBiotix in its N-PORT filings yet. We sweep new filings monthly.